Tigenix NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Tigenix NV to sell Dutch manufacturing facility to PharmaCell
Tigenix NV:Signs an agreement for the sale of its Dutch production facility to PharmaCell B.V, a European-based contract manufacturing organization active in the area of cell therapy and regenerative medicine, for a total consideration of 5.75 million euros.Says PharmaCell is to acquire the shares of TiGenix's wholly owned subsidiary TiGenix B.V., which holds the Dutch manufacturing facility.Says under the terms of the agreement, TiGenix will receive an upfront payment of 3.5 million euros when the sale becomes effective and a final payment of 750,000 euros after three years.Says in addition, ChondroCelect will continue to be manufactured at the facility under a long-term manufacturing agreement, under the terms of which TiGenix will benefit from a cost relief of 1.5 million euros during the first three years.Says the sale of TiGenix B.V. is expected to become effective in the coming months.Says closing of the transaction is subject to confirmation by the relevant authority that the TiGenix B.V. is authorized to produce other products than ChondroCelect, as well as confirmation in respect of the financing of the transaction by PharmaCell.
Latest Developments for Tigenix NV
- Tigenix NV Completes EUR 12 Million Capital Increase
- Grifols SA’s Subsidiary Acquires 21.30% Stake In TiGenix NV
- Tigenix NV Reports Positive Phase IIa Study Results In Refractory Rheumatoid Arthritis With Allogeneic Stem Cell Product Cx611
- Tigenix NV Announces Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells 'Cx611'
- Share this
- Digg this